Abstract
The use of nanoparticles as platforms or vehicles for applications in nanomedicine, such as drug delivery and medical imaging, has been widely reported in the literature. A key area of potential improvement in the development and implementation of nanoparticles is the design of surface treatments to maximize residence time in the bloodstream. Major obstacles to the prolonged circulation of nanoparticles include complement activation and opsonization, both of which contribute to the removal of foreign matter from the vasculature. A greater understanding of the mechanisms through which nanoparticles interact with the complement system of innate immunity may be necessary in future endeavours to optimize nanoparticle design. The range of experimental techniques available for measuring complement interaction is presented. In particular, an in vitro hemolytic complement consumption assay called the CH50 method is compared with alternative complement measurement techniques and cellular uptake studies in order to demonstrate its effectiveness as a quantitative evaluation of overall complement interaction. Moreover, establishing the usefulness of CH50 results as predictors of in vivo behaviour is identified as a critical area for future research.
Keywords: CH50 assay, complement activation, hemolytic assay, nanoparticles, opsonization, protein interaction, stealth, toxicity, Plasma Protein, vasculature
Current Drug Delivery
Title: CH50: A Revisited Hemolytic Complement Consumption Assay for Evaluation of Nanoparticles and Blood Plasma Protein Interaction
Volume: 8 Issue: 3
Author(s): Ameena Meerasa, Jasper G. Huang and Frank X. Gu
Affiliation:
Keywords: CH50 assay, complement activation, hemolytic assay, nanoparticles, opsonization, protein interaction, stealth, toxicity, Plasma Protein, vasculature
Abstract: The use of nanoparticles as platforms or vehicles for applications in nanomedicine, such as drug delivery and medical imaging, has been widely reported in the literature. A key area of potential improvement in the development and implementation of nanoparticles is the design of surface treatments to maximize residence time in the bloodstream. Major obstacles to the prolonged circulation of nanoparticles include complement activation and opsonization, both of which contribute to the removal of foreign matter from the vasculature. A greater understanding of the mechanisms through which nanoparticles interact with the complement system of innate immunity may be necessary in future endeavours to optimize nanoparticle design. The range of experimental techniques available for measuring complement interaction is presented. In particular, an in vitro hemolytic complement consumption assay called the CH50 method is compared with alternative complement measurement techniques and cellular uptake studies in order to demonstrate its effectiveness as a quantitative evaluation of overall complement interaction. Moreover, establishing the usefulness of CH50 results as predictors of in vivo behaviour is identified as a critical area for future research.
Export Options
About this article
Cite this article as:
Meerasa Ameena, G. Huang Jasper and X. Gu Frank, CH50: A Revisited Hemolytic Complement Consumption Assay for Evaluation of Nanoparticles and Blood Plasma Protein Interaction, Current Drug Delivery 2011; 8 (3) . https://dx.doi.org/10.2174/156720111795256165
DOI https://dx.doi.org/10.2174/156720111795256165 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Potential of Graphene Oxide and Reduced Graphene Oxide in
Diagnosis and Treatment of Cancer
Current Medicinal Chemistry Emerging In Vitro Tools to Evaluate Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions
Current Drug Discovery Technologies β-Galactosylated Alkyl-oligoamine Derivatives of Polyethylenimine Enhanced pDNA Delivery into Hepatic Cells with Reduced Toxicity
Current Nanoscience Biomolecular Pathogenesis of Borderline Ovarian Tumors: Focusing Target Discovery Through Proteogenomics
Current Cancer Drug Targets Synthesis and Biological Evaluation of Licofelone Derivatives as Anticancer and Anti-inflammatory Agents
Letters in Drug Design & Discovery Data Reduction Methods for Application of Fluorescence Correlation Spectroscopy to Pharmaceutical Drug Discovery
Current Pharmaceutical Biotechnology Nanochannel Systems for Personalized Therapy and Laboratory Diagnostics
Current Pharmaceutical Biotechnology Multi-Target Inhibitors for Proteins Associated with Alzheimer: In Silico Discovery using Fragment-Based Descriptors
Current Alzheimer Research Role of ABC Transporters in Veterinary Drug Research and Parasite Resistance
Current Drug Delivery Nano-QSPR Modelling of Carbon-Based Nanomaterials Properties
Current Topics in Medicinal Chemistry A Comparative Study Between the Leaf and Flowers of Some Asteraceae Plants With Respect to Their Antioxidant Activity Compounds
Current Nutrition & Food Science Cardioprotective Effects of the Polyphenol Hydroxytyrosol from Olive Oil
Current Drug Targets Iron Oxide Nanoparticles: An Insight into their Biomedical Applications
Current Medicinal Chemistry Synthesis of Functionalized Chromenes from Meldrum’s Acid, 4- Hydroxycoumarin, and Ketones or Aldehydes
Combinatorial Chemistry & High Throughput Screening Ganoderma lucidum: A Potential for Biotechnological Production of Anti-Cancer and Immunomodulatory Drugs
Recent Patents on Anti-Cancer Drug Discovery QSAR as a Tool for the Development of Potent Antiproliferative Agents by Inhibition of Choline Kinase
Current Computer-Aided Drug Design Clinical Proteomics in Cancer Research – Promises and Limitations of Current Two-Dimensional Gel Electrophoresis
Current Medicinal Chemistry Novel Synthesis of 4-Benzylidene-2-((1-phenyl-3,4-dihydroisoquinoline-2(1H)-yl)methyl) oxazol-5(4H)-one Derivatives Using 1,2,3,Tetrahydroisoquinoline and their Antimicrobial Activity
Current Organic Synthesis Development and Production of Commercial Therapeutic Monoclonal Antibodies in Mammalian Cell Expression Systems: An Overview of the Current Upstream Technologies
Current Pharmaceutical Biotechnology Ribonucleases and ImmunoRNases as Anticancer Drugs
Current Pharmaceutical Design